| __timestamp | Verona Pharma plc | Wave Life Sciences Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 1802274 | 2999000 |
| Thursday, January 1, 2015 | 2512761 | 10393000 |
| Friday, January 1, 2016 | 2894488 | 15994000 |
| Sunday, January 1, 2017 | 8096274 | 26975000 |
| Monday, January 1, 2018 | 7985229 | 39509000 |
| Tuesday, January 1, 2019 | 8994597 | 48869000 |
| Wednesday, January 1, 2020 | 29772000 | 42510000 |
| Friday, January 1, 2021 | 33907000 | 46105000 |
| Saturday, January 1, 2022 | 26579000 | 50513000 |
| Sunday, January 1, 2023 | 49868547 | 51292000 |
Cracking the code
In the competitive world of biotechnology, managing expenses is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Verona Pharma plc and Wave Life Sciences Ltd. over the past decade. From 2014 to 2023, Wave Life Sciences consistently outpaced Verona Pharma in SG&A spending, peaking at approximately $51 million in 2023, a 70% increase from 2014. Verona Pharma, while starting at a modest $1.8 million in 2014, saw a dramatic rise, reaching nearly $50 million by 2023, marking a staggering 2,670% increase. This trend highlights Verona Pharma's aggressive expansion strategy. Understanding these financial dynamics offers insights into each company's operational focus and strategic priorities, providing a window into their future trajectories in the biotech landscape.
Eli Lilly and Company and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared
Novo Nordisk A/S or Verona Pharma plc: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Verona Pharma plc
Walgreens Boots Alliance, Inc. vs Verona Pharma plc: SG&A Expense Trends
Lantheus Holdings, Inc. and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared
Verona Pharma plc and CymaBay Therapeutics, Inc.: SG&A Spending Patterns Compared
Verona Pharma plc vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Verona Pharma plc or Novavax, Inc.
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and Wave Life Sciences Ltd.
Selling, General, and Administrative Costs: Protagonist Therapeutics, Inc. vs Wave Life Sciences Ltd.
Mesoblast Limited and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Wave Life Sciences Ltd. or MiMedx Group, Inc.